Acquired by Karl Storz in Sep 2024
ASXC - Asensus Surgical, Inc.
NYSE
->
Healthcare
->
Medical Devices
Durham,
United States
Type: Equity
ASXC price evolution
ASXC
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.68 | $3.51 | $0.7 | |
| Inventory | $5.96 | $7.17 | $6.7 | |
| Total current assets | $19.25 | $36.39 | $45.9 | |
| Long term investments | ||||
| Property, plant & equipment | $13.56 | $14.12 | $14.2 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $40.81 | $59.09 | $70.7 | |
| Current liabilities | ||||
| Accounts payable | $4.04 | $4.14 | $4.5 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $19.29 | $12.63 | $12.1 | |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $27.79 | $25.67 | $23.5 | |
| Shareholders' equity | ||||
| Retained earnings | -$961.87 | -$939.37 | -$922.1 | |
| Other shareholder equity | -$1.1 | -$0.61 | -$1.8 | |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $16.36 | |||
| Short term investments | ||||
| Net receivables | $3.51 | $2.81 | $2.06 | $1.11 |
| Inventory | $7.17 | $8.28 | $8.63 | $10.03 |
| Total current assets | $36.39 | $86.87 | $113.3 | $34.01 |
| Long term investments | ||||
| Property, plant & equipment | $14.12 | $14.49 | $16.32 | $10.34 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $44.24 | |||
| Total investments | ||||
| Total assets | $59.09 | $116.05 | $186.47 | $78.26 |
| Current liabilities | ||||
| Accounts payable | $4.14 | $3.35 | $3.45 | $1.97 |
| Deferred revenue | $0.79 | |||
| Short long term debt | ||||
| Total current liabilities | $12.63 | $10.41 | $9.85 | $10.28 |
| Long term debt | $1.59 | |||
| Total noncurrent liabilities | $6.41 | |||
| Total debt | ||||
| Total liabilities | $25.67 | $16.41 | $17.23 | $16.69 |
| Shareholders' equity | ||||
| Retained earnings | -$939.37 | -$860.93 | -$785.37 | -$722.91 |
| Other shareholder equity | -$0.61 | -$2.39 | -$0.26 | $2.97 |
| Total shareholder equity | ||||
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.12 | $5.43 | $1.09 | |
| Cost of revenue | ||||
| Gross Profit | -$1.93 | $1.17 | -$1.78 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $22.7 | $16.79 | $18.48 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.05 | $0.18 | $0.06 | |
| Interest expense | $0.13 | $0.28 | $0.41 | |
| Net income | ||||
| Net income | -$22.5 | -$17.23 | -$18.32 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $8.58 | $7.09 | $3.17 | |
| Cost of revenue | ||||
| Gross Profit | -$4.58 | -$3.79 | -$1.99 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $74.52 | $70.47 | $58.56 | |
| Operating income | -$60.39 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.31 | $0.32 | -$1.52 | |
| Interest expense | $1.55 | $0.73 | $0.02 | |
| Net income | ||||
| Net income | -$78.43 | -$75.56 | -$59.31 | |
| Income (for common shares) | ||||
| (in millions $) | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $3 | $64.51 | $57.08 | $36.3 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0.81 | $9.63 | $9.45 | -$0.29 |
| Effect of exchange rate | -$0.06 | $0.76 | -$0.47 | $0.75 |
| Change in cash and equivalents | -$10.26 | $11.27 | $15.81 | $1.56 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$59.31 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$46.67 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $64.51 | $47.54 | -$119.67 | -$0 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $9.63 | -$0.33 | $161.71 | $53.37 |
| Effect of exchange rate | $0.76 | -$0.08 | $0.38 | $0.27 |
| Change in cash and equivalents | $11.27 | -$11.81 | $1.76 | $6.96 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |